Alan C. Herman
Plus aucun poste en cours
Profil
Alan C.
Herman was the founder of Coherus BioSciences, Inc. (2010) and Windrose Analytica, Inc. (2005), where he held the titles of Chief Scientific Officer and Chief Executive Officer, respectively.
Dr. Herman also founded Windrose Medical Properties Trust.
He held former positions as Senior Director-Quality Control at Tercica, Inc., Principal at Merck & Co., Inc., and Chief Scientific Officer & VP-Product Development at Ajinomoto Althea, Inc. (2009-2011).
Dr. Herman earned a doctorate degree from Duke University and undergraduate and graduate degrees from Indiana University of Pennsylvania.
Anciens postes connus de Alan C. Herman
| Sociétés | Poste | Fin |
|---|---|---|
Ajinomoto Althea, Inc.
 Ajinomoto Althea, Inc. Medical SpecialtiesHealth Technology Ajinomoto Althea, Inc. provides biopharmaceutical contract development and manufacturing services to biotechnology and pharmaceutical companies worldwide. It offers development services in the areas of process development, protein formulation technology, analytical development and validation, and regulatory support. The company was founded by Magda Marquet and Francois Ferre in 1998 and is headquartered in San Diego, CA. | Directeur Technique/Scientifique/R&D | 01/04/2011 |
| Windrose Analytica, Inc. | Directeur Général | 01/01/2009 |
| COHERUS BIOSCIENCES, INC. | Fondateur | - |
Windrose Medical Properties Trust
 Windrose Medical Properties Trust Real Estate Investment TrustsFinance Windrose Medical Properties Trust operated real estate investment trusts. It provided business planning, design, development, finance and management services to healthcare systems, physician groups, and third party medical property owners. Its portfolio includes medical office buildings, outpatient treatment, diagnostic centers, and ambulatory surgery centers. The company was founded in 2002 and was headquartered in Indianapolis, IN. | Fondateur | - |
Tercica, Inc.
 Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | Corporate Officer/Principal | - |
Formation de Alan C. Herman
| Duke University | Doctorate Degree |
| Indiana University of Pennsylvania | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| COHERUS BIOSCIENCES, INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
Windrose Medical Properties Trust
Windrose Medical Properties Trust Real Estate Investment TrustsFinance Windrose Medical Properties Trust operated real estate investment trusts. It provided business planning, design, development, finance and management services to healthcare systems, physician groups, and third party medical property owners. Its portfolio includes medical office buildings, outpatient treatment, diagnostic centers, and ambulatory surgery centers. The company was founded in 2002 and was headquartered in Indianapolis, IN. | Finance |
Tercica, Inc.
Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | Health Technology |
Ajinomoto Althea, Inc.
Ajinomoto Althea, Inc. Medical SpecialtiesHealth Technology Ajinomoto Althea, Inc. provides biopharmaceutical contract development and manufacturing services to biotechnology and pharmaceutical companies worldwide. It offers development services in the areas of process development, protein formulation technology, analytical development and validation, and regulatory support. The company was founded by Magda Marquet and Francois Ferre in 1998 and is headquartered in San Diego, CA. | Health Technology |
| Windrose Analytica, Inc. |
